{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:57:18Z","timestamp":1760122638453},"reference-count":32,"publisher":"Impact Journals, LLC","issue":"13","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,3,28]]},"DOI":"10.18632\/oncotarget.15397","type":"journal-article","created":{"date-parts":[[2017,2,22]],"date-time":"2017-02-22T07:04:21Z","timestamp":1487747061000},"page":"22299-22303","source":"Crossref","is-referenced-by-count":11,"title":["Membranous nephropathy associated with hepatitis C virus infection treated with corticosteroids and Ledipasvir-Sofosbuvir: a case report and review of literature"],"prefix":"10.18632","volume":"8","author":[{"given":"Qinjie","family":"Weng","sequence":"first","affiliation":[{"name":"Department of Nephrology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingyuan","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxia","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2017,2,16]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"149","DOI":"10.5414\/CNP69149","article-title":"Hepatitis C virus-related kidney disease: an overview","volume":"69","author":"Rostaing","year":"2008","journal-title":"Clin Nephrol"},{"key":"2","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0272-6386(03)00828-X","article-title":"Hepatitis C and renal disease: an update","volume":"42","author":"Hoofnagle","year":"2003","journal-title":"American journal of kidney diseases"},{"key":"3","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1159\/000333772","article-title":"Hepatitis C and renal disease: epidemiology, diagnosis, pathogenesis and therapy","volume":"176","author":"Rostaing","year":"2012","journal-title":"Contributions to nephrology"},{"key":"4","doi-asserted-by":"crossref","first-page":"7544","DOI":"10.3748\/wjg.v20.i24.7544","article-title":"Hepatitis C virus associated glomerulopathies","volume":"20","author":"Yildiz","year":"2014","journal-title":"World journal of gastroenterology"},{"key":"5","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1517\/14656566.2015.1066333","article-title":"Treatment of hepatitis C-related kidney disease","volume":"16","author":"Donato","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"6","first-page":"256","article-title":"Ledipasvir\/Sofosbuvir (harvoni): improving options for hepatitis C virus infection","volume":"40","author":"Hughes","year":"2015","journal-title":"P T"},{"key":"7","unstructured":"Gilead Sciences. Harvoni (ledipasvir\/sofosbuvir) prescribing information. http:\/\/wwwgileadcom\/. 2014."},{"key":"8","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s12072-015-9629-x","article-title":"A review of the burden of hepatitis C virus infection in China, Japan, South Korea and Taiwan","volume":"9","author":"Li","year":"2015","journal-title":"Hepatol Int"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Cacoub, Renou, Rosenthal, Cohen, Loury, Loustaud-Ratti, Yamamoto, Camproux, Hausfater, Musset, Veyssier, Raguin, Piette. Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. The GERMIVIC. Groupe d\u2019Etude et de Recherche en Medecine Interne et Maladies Infectieuses sur le Virus de l\u2019Hepatite C. Medicine (Baltimore). 2000; 79:47\u201356.","DOI":"10.1097\/00005792-200001000-00005"},{"key":"10","first-page":"3574","article-title":"Hepatitis C viral infection in a Chinese hemodialysis unit","volume":"123","author":"Wang","year":"2010","journal-title":"Chin Med J (Engl)"},{"key":"11","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/0272-6386(95)90095-0","article-title":"Cryoglobulinemic glomerulonephritis: a membranoproliferative glomerulonephritis induced by hepatitis C virus","volume":"25","author":"Fornasieri","year":"1995","journal-title":"American journal of kidney diseases"},{"key":"12","first-page":"446","article-title":"Hepatitis C virus-related kidney disease: various histological patterns","volume":"74","author":"Oohashi","year":"2010","journal-title":"Clin Nephrol"},{"key":"13","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1681\/ASN.V62220","article-title":"Hepatitis C virus infection and membranoproliferative glomerulonephritis in Japan","volume":"6","author":"Tamura","year":"1995","journal-title":"J Am Soc Nephrol"},{"key":"14","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1056\/NEJM199302183280711","article-title":"Immune-complex glomerulonephritis\u2014deposits plus interest","volume":"328","author":"Appel","year":"1993","journal-title":"New England Journal of Medicine"},{"key":"15","first-page":"434","article-title":"Hepatitis C virus and its renal manifestations: a review and update","volume":"8","author":"Gurakar","year":"2012","journal-title":"Gastroenterology & Hepatology"},{"key":"16","first-page":"141","article-title":"Hepatitis C virus associated membranous glomerulonephritis","volume":"44","author":"Johnson","year":"1995","journal-title":"Clin Nephrol"},{"key":"17","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.3109\/0886022X.2013.815568","article-title":"Long-term response to peginterferon in hepatitis C virus-associated nephrotic syndrome from focal segmental glomerulosclerosis","volume":"35","author":"Patel","year":"2013","journal-title":"Renal failure"},{"key":"18","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1159\/000345515","article-title":"Antiviral therapy for HCV-associated cryoglobulinemic glomerulonephritis: case report and review of the literature","volume":"35","author":"Messa","year":"2012","journal-title":"Kidney & blood pressure research"},{"key":"19","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/hep.27950","article-title":"guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus","volume":"62","author":"Hepatitis","year":"2015","journal-title":"Hepatology"},{"key":"20","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1093\/ndt\/gfr236","article-title":"Effect of interferon-alpha-based antiviral therapy on hepatitis C virus-associated glomerulonephritis: a meta-analysis","volume":"27","author":"Wei","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"21","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1517\/14656566.2015.1019862","article-title":"Perspectives of fixed daily dose of sofosbuvir and ledipasvir for the treatment of chronic hepatitis","volume":"16","author":"Floreani","year":"2015","journal-title":"C. Expert Opin Pharmacother"},{"key":"22","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jhep.2013.03.030","article-title":"NS5A inhibitors in the treatment of hepatitis C","volume":"59","author":"Pawlotsky","year":"2013","journal-title":"J Hepatol"},{"key":"23","unstructured":"Gilead Sciences. Sovaldi (sofosbuvir) prescribing information. http:\/\/wwwgileadcom\/. 2014."},{"key":"24","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.antiviral.2014.04.008","article-title":"Beyond sofosbuvir: what opportunity exists for a better nucleoside\/nucleotide to treat hepatitisC?","volume":"107","author":"Sofia","year":"2014","journal-title":"Antiviral Res"},{"key":"25","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection","volume":"370","author":"Buti","year":"2014","journal-title":"The New England journal of medicine"},{"key":"26","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","article-title":"Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis","volume":"370","author":"Herring","year":"2014","journal-title":"The New England journal of medicine"},{"key":"27","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1053\/j.gastro.2013.11.007","article-title":"Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection","volume":"146","author":"Pang","year":"2014","journal-title":"Gastroenterology"},{"key":"28","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","article-title":"Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection","volume":"370","author":"Pockros","year":"2014","journal-title":"The New England journal of medicine"},{"key":"29","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1007\/s40262-016-0397-0","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Ledipasvir\/Sofosbuvir, a Fixed-Dose Combination Tablet for the Treatment of Hepatitis C","volume":"55","author":"Kearney","year":"2016","journal-title":"Clinical pharmacokinetics"},{"key":"30","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/ajg.2015.391","article-title":"Harvoni (Ledipasvir With Sofosbuvir)-Induced Renal Injury","volume":"111","author":"Jhaveri","year":"2016","journal-title":"The American journal of gastroenterology"},{"key":"31","first-page":"213","article-title":"Management of patients with hepatitis C infection and renal disease","volume":"7","author":"Chavalitdhamrong","year":"2015","journal-title":"World journal of hepatology"},{"key":"32","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1517\/14740338.2015.1053868","article-title":"Safety analysis of sofosbuvir and ledipasvir for treating hepatitis C","volume":"14","author":"Younossi","year":"2015","journal-title":"Expert opinion on drug safety"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.15397","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,24]],"date-time":"2022-07-24T15:11:48Z","timestamp":1658675508000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.15397"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,16]]},"references-count":32,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2017,3,28]]}},"alternative-id":["15397","28223549"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.15397","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,16]]}}}